Form 4: FibroBiologics General Counsel Receives Stock Options

Ruben A. Garcia, General Counsel of FibroBiologics, Inc., was granted stock options to purchase 189,000 shares of common stock on March 26, 2025.

Summary

• Ruben A. Garcia, the General Counsel of FibroBiologics, Inc., received stock options on March 26, 2025.
• The options grant him the right to purchase 189,000 shares of the company's common stock at an exercise price of $1.04 per share.
• The options vest over a period of four years; 25% vest on the one-year anniversary of the grant date, and the remaining 75% vest in 36 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The granting of stock options aligns the General Counsel's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant (189,000 shares) and the vesting schedule (25% after one year, then monthly) are typical for executive-level stock options.
• Comparable companies like CRISPR Therapeutics or Editas Medicine also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the General Counsel to contribute to the company's success.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, FibroBiologics, FBLG, General Counsel, Ruben A. Garcia, beneficial ownership, Form 4, securities